Last reviewed 2026-05-14 · How we verify

injection of NMBA

NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.

NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction. Used for Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation.

At a glance

Mechanism of action

NMBAs competitively or non-competitively inhibit acetylcholine receptors at the motor end plate, preventing muscle contraction. This is used during anesthesia and intubation to facilitate surgical access and mechanical ventilation. The effect is reversible and wears off as the drug is metabolized or cleared.

Approved indications

• Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation

Common side effects

• Residual neuromuscular blockade
• Histamine release (with certain agents)
• Anaphylaxis
• Malignant hyperthermia (in susceptible patients)

Key clinical trials

• Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient (PHASE3)
• A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) (PHASE4)
• Assessment Study of the Effect of NMBA on Bowel Peristalsis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• injection of NMBA CI brief — competitive landscape report
• injection of NMBA updates RSS · CI watch RSS
• Fondation Ophtalmologique Adolphe de Rothschild portfolio CI